LLY
Eli Lilly and Company
- Selling, general and administrative, 2025
- $11.1B
- YoY, 2025
- +29.1%
- 5-year CAGR
- +12.6%
- 10-year CAGR
- +5.4%
Selling, general and administrative
Selling, general and administrative by fiscal year
| Period | SG&A | YoY |
|---|---|---|
| 2025 | $11.1B | +29.1% |
| 2024 | $8.6B | +16.1% |
| 2023 | $7.4B | +15.0% |
| 2022 | $6.4B | +0.1% |
| 2021 | $6.4B | +5.1% |
| 2020 | $6.1B | −1.5% |
| 2019 | $6.2B | +4.0% |
| 2018 | $6.0B | −0.1% |
| 2017 | $6.0B | −8.4% |
| 2016 | $6.5B | −0.1% |
| 2015 | $6.5B | −1.3% |
| 2014 | $6.6B | −7.1% |
| 2013 | $7.1B | −5.2% |
| 2012 | $7.5B | −4.6% |
| 2011 | $7.9B | +11.7% |
| 2010 | $7.1B | +2.3% |
| 2009 | $6.9B | +4.0% |
| 2008 | $6.6B | +8.7% |
| 2007 | $6.1B | — |